Acellular artificial antigen ... signal 2') and cytokine release ('signal 3'). Nanoengineering Approaches for Next-generation aAPCs Most current-generation aAPCs employ static isotropic ...

The density of tumor antigen in conjunction with major histocompatibility complex (MHC) class I molecules on the cell surface ... the middle of the signal peptide; and (3) pCOC-IL-2, expressing ...

Tumor antigens are captured and displayed by antigen processing and presentation machinery (APM) on the cell surface by HLA ... SCCs show a 49.3% objective response rate to PD-1 therapy, while ...

coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. A low dose (approximately 1.5×10 ...

This review focuses on agents that are either approved or in phase 2 or phase 3 trials in kidney ... effector functions. Antigen triggers T-cell receptors (TCRs) (signal 1) and synapse formation.

The tumor microenvironment, tumor immunogenicity, antigen presentation ... cell receptor recognition of corresponding antigens on major histocompatibility complexes (MHCs) expressed by ...

98% (48/49) demonstrated a T cell response to either antigen following vaccination ... 6 of 15 patients in the GEO-CM04S1 arm achieved ≥3-fold increases in Spike or Nucleocapsid-specific ...